Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2020 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results